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513 DOES THE HIP POWDER OF ROSA CANINA (ROSEHIP)
REDUCE PAIN IN OSTEOARTHRITIS PATIENTS? – A
META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS
R. Christensen1, E.M. Bartels2, R.D. Altman3, A. Astrup4, H. Bliddal1.
1The Parker Institute: Musculoskeletal Statistics Unit, Frederiksberg
Hospital, Copenhagen, DENMARK, 2Copenhagen University Library,
Copenhagen, DENMARK, 3David Geffen School of Medicine, University
of California, Los Angeles, CA, USA, 4Department of Human Nutrition,
Faculty of Life Sciences, University of Copenhagen, Copenhagen,
DENMARK
Purpose: Meta-analysis of randomized controlled trials (RCTs) – of a hip
powder of Rosa canina (rosehip) preparation for symptomatic treatment
of osteoarthritis (OA), in order to estimate the empirical efﬁcacy as a
pain-reducing compound.
Methods: RCTs from systematic searches were included if they explicitly
stated that OA patients were randomized to either rosehip or placebo.
The primary outcome was reduction in pain calculated as effect size
(ES), deﬁned as the standardized mean difference (SMD). As secondary
analysis the number of responders to therapy was analyzed as Odds
Ratios (OR), and expressed as the Number Needed to Treat (NNT).
Restricted Maximum Likelihood (REML) methods were applied for the
meta-analyses using mixed effects models.
Results: The three studies (287 patients and a median trial-duration
of 3 months) – all supported by the manufacturer (Hyben-Vital Interna-
tional) – showed a reduction in pain scores by rosehip powder (145 pa-
tients) compared to placebo (142 patients): ES of 0.37 [95% conﬁdence
interval (CI): 0.13−0.60], P = 0.002. Test for homogeneity seemed to
support that the efﬁcacy was consistent across trials (I-square = 0%).
Thus it seems reasonable to assume that the three studies were mea-
suring the same overall effect. It seemed twice as likely that a patient
allocated to rosehip powder would respond to therapy, compared to
placebo (OR=2.19; P=0.0009); corresponding to a NNT of six (95% CI:
4−13) patients (ﬁgure).
Conclusions: Although based on a sparse amount of data, the results of
the present meta-analysis indicate that rosehip powder does reduce pain;
accordingly it may be of interest as a nutraceutical, although its efﬁcacy
and safety need evaluation and independent replication in a future large-
scale/long-term trial.
514 RADIOGRAPHIC STATUS IN KNEE OSTEOARTHRITIS (OA) IS
NOT RELATED TO BMI, AND HAS NO IMPORTANCE FOR
THE POSSIBILITY OF WEIGHT LOSS DURING A PERIOD OF
INTENSIVE DIETARY INTERVENTION: THE CAROT STUDY
B.F. Riecke1, R. Christensen1, M. Boesen1, P. Christensen1, A. Astrup2,
L.S. Lohmander3, H. Bliddal1. 1The Parker Institute, Frederiksberg
Hospital, Copenhagen, DENMARK, 2Department of Human Nutrition,
Faculty of Life Science, Copenhagen University, Copenhagen,
DENMARK, 3Department of Orthopaedics, Clinical Sciences Lund, Lund
University, Lund, SWEDEN
Purpose: Obesity and OA coexist in an increasing part of the population,
and the two diseases intertwine in several ways. Body-mass index (BMI)
is the single most important risk factor for knee OA and awareness of
the beneﬁt of weight reduction should be emphasized at all stages of the
disease.
To assess the association between the Kellgren-Lawrence (K-L) score
and BMI in obese patients with knee OA among the included patients and
explore whether the K-L score could predict the amount of weight loss
using low (LED) and very low-energy diets (VLED) in patients following
the Cambridge diet for 8 weeks in the CAROT-study (NCT00655941).
Methods: Prior to inclusion in the CAROT-study at the Parker Insti-
tute, Frederiksberg Hospital, and thus commencing the Cambridge-diet
program, we obtained standing radiographs from 47 obese (BMI> 30)
patients suffering from OA in one or both knees, to fulﬁl both the clinical
and radiological ACR criteria for knee OA. The subjects were also
>50 years, spoke Danish and were motivated for weight loss. Exclusion
criteria were: bilateral alloplasty of the knees; ongoing or planned surgery;
ongoing or planned alternative weight loss programme; and intellectual
disability. The mean age of the population was 62.8 years (SD: 6.9;
range: 50−75 y), with only three (6.4%) of the patients being males. The
radiographic severity of OA was assessed using the K-L scale for the
medial, lateral and patellar compartments. A total K-L-score (sum of all 3
compartments) was calculated (range:0−12). All patients were weighed
before and after the 8 weeks diet period with the same equipment.
The statistical analysis was based on a non-responder intention-to-treat
(ITT) population (baseline observation carried forward). In the diet period
the patients only consumed products from the ‘Cambridge Health &
Weight Plan’, providing them a daily calorie intake between 415 kCal and
810 kCal.
Results: The median total K-L score was 5 (1−10), medial compartment
2 (0−4), lateral compartment 1 (0−3), and the patellar compartment 2
(0−4). Before the diet period the patients had a mean BMI of 38.0 kg/m2
(SD: 3.6; 31.0−48.4) corresponding to an average body weight of 102.4 kg
(SD:13.2; 84.4–143.8 kg). There was no correlation between K-L score
and BMI at baseline (r = 0.21; P=0.17) with less than ﬁve percent of
the variation in K-L score being explained by the BMI (R-squared <5%).
After the diet period of 8 weeks only one patient (2.1%) withdrew from
the project, however, the ITT patients (n = 47) experienced a highly
signiﬁcant weight reduction (P< 0.0001) of 11.4 kg (95%CI 10.2−12.5 kg),
corresponding to an average loss of 11.0% of the initial body weight. The
percentage of body weight lost was not associated with the K-L score
neither of the whole joint nor its separate compartments.
Conclusions: In this group of obese Danish patients with knee OA there
was no indication of a correlation between radiographic severity and
BMI. The K-L score was not associated with the amount of weight-loss.
Whereas knee OA may often be perceived as a barrier to successful
weight loss these patients achieved meaningful weight-loss on the ‘Cam-
bridge Health & Weight Plan’. This suggests that any knee OA patient
with concomitant obesity may be enrolled in an effective weight reducing
program. The results show that radiographic knee status is not important
for a weight loss: In other words, bad knees are no excuse for not loosing
weight.
515 DOES KNEE MALALIGNMENT MEDIATE THE EFFECTS OF
QUADRICEPS STRENGTHENING ON KNEE ADDUCTION
MOMENT, PAIN AND FUNCTION IN MEDIAL KNEE
OSTEOARTHRITIS?
B-W. Lim1, R. Hinman1, T. Wrigley1, L. Sharma2, K. Bennell1.
1University of Melbourne, Melbourne, AUSTRALIA, 2Northwestern
University, Chicago, IL, USA
Purpose: To examine whether the effects of 12 weeks of quadriceps
strengthening on the knee adduction moment (KAM), pain and function
in people with medial knee OA differ in those with and without varus
malalignment.
Methods: A single-blind randomized controlled trial involving 107 com-
munity volunteers with medial knee OA was conducted. Participants
were stratiﬁed according to knee malalignment (more varus or more
neutral) and then randomized into either a 12-week supervised home
based quadriceps strengthening (QS) group or a control group with no
intervention. The primary outcome was the KAM measured using three-
dimensional gait analysis. Secondary outcomes included the Western
Ontario and McMaster Universities Osteoarthritis Index (WOMAC) mea-
suring pain and physical function, step test, stair climb test and maximum
quadriceps isometric strength. Analyses of covariance were carried out
based on intention-to-treat principles.
Results: Quadriceps strengthening did not signiﬁcantly alter the KAM
in either the more malaligned or the more neutral group (unadjusted
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KAM=0.12 and 0.05%Nm/BW.HT respectively). Function did not improve
signiﬁcantly following quadriceps strengthening in either alignment group
but there was a signiﬁcant improvement in knee pain in the more neutral
group only (P< 0.001).
Conclusions: Quadriceps strengthening did not have any signiﬁcant
effect on the KAM in participants with either more varus or more neutral
alignment. The beneﬁts of quadriceps strengthening on pain were more
evident in those with more neutral alignment. Knee alignment thus repre-
sents a local mechanical factor that can mediate symptomatic outcome
from exercise interventions in knee OA.
516 CURCUMIN (DIFERULOYLMETHANE) BLOCKS
Il-1b STIMULATED GLYCOSAMINOGLYCAN AND
PROSTAGLANDIN E2 RELEASE FROM CARTILAGE
EXPLANTS IN AN IN VITRO MODEL OF OSTEOARTHRITIS
A.L. Clutterbuck1, A. Mobasheri1, T.C. Rogers2, J. Wiseman2,
D. Allaway3, P. Harris3. 1School of Veterinary Medicine and Science,
University of Nottingham, Nottingham, UNITED KINGDOM, 2School of
Biosciences, University of Nottingham, Nottingham, UNITED KINGDOM,
3WALTHAM Centre for Pet Nutrition, Melton Mowbray, UNITED
KINGDOM
Purpose: Curcumin is the principal biologically active component of
turmeric (Curcuma longa). Although it has been extensively investigated
for its anti-tumor, antioxidant and anti-inﬂammatory properties in various
cell models, few studies have explored its potential for counteracting
inﬂammatory and catabolic pathways in articular cartilage. Curcumin
has been shown to suppress the NFúB pathway and protect isolated
human chondrocytes from the catabolic effects of Il-1b. The aim of this
study was to see if curcumin could reduce glycosaminoglycan (GAG)
and prostaglandin E2 (PGE2) release from explants of equine articular
cartilage incubated with recombinant equine Il-1b in an in vitro model of
inﬂammatory OA.
Methods: Normal articular cartilage was obtained from weight bearing
regions of the metacarpophalangeal joints of three horses euthanized
for purposes other than for research. Cartilage explants were incubated
with 10 ng/ml equine recombinant Il-1b and curcumin at 25 mM, 50mM,
75mM or 100mM at 37ºC for 5 days in serum free DMEM. The dimethyl-
methylene blue (DMMB) assay was used to measure GAG release and
PGE2 immunoassays were used to assess the potential anti-inﬂammatory
effects of curcumin. Results were statistically analyzed using a one way
ANOVA with a Newman-Keuls post hoc test. Statistical signiﬁcance was
set at P <0.05.
Results: Curcumin signiﬁcantly reduced Il-1b-stimulated GAG release in
the explants at 50mM (P <0.05), 75mM (P < 0.01) and 100mM (P < 0.001).
PGE2 release in response to Il-1b exposure was diminished by curcumin
at 25mM, 50mM, 75mM and 100mM (P < 0.001).
Conclusions: This study demonstrates that micromolar concentrations
of curcumin exert signiﬁcant anti-catabolic and anti-inﬂammatory effects
in our inﬂammatory model of OA. These results support the use of
this cartilage explant model as a screening assay for novel functional
ingredients.
Acknowledgements: This work was supported by the BBSRC
(BBS/S/M/2006/13141) and the WALTHAM Centre for Pet Nutrition.
517 DUROLANE PROVIDES ANTI-NOCICEPTIVE EFFECTS IN A
MODEL OF ARTICULAR JOINT PAIN
M. Bottger1, H-G. Schaible1, A.J. Harrison2. 1Klinikum der
Friedrich-Schiller Universitat, Jena, GERMANY, 2Smith & Nephew
Group Research Centre, York, UNITED KINGDOM
Purpose: The degenerative joint disease, osteoarthritis (OA), is char-
acterised with a loss of cartilage and increased pain from affected
joints. It is this chronic pain which most patients associate with their
condition. Non-steroidal anti-inﬂammatory drugs (NSAIDs) are used to
treat inﬂammation and as a knock on effect, through the reduction of
COX2 and prostaglandin E2 (PGE2), can reduce the pain associated
with OA. However, NSAIDs are generally administered systemically and
can exhibit harmful side effects. Hyaluronans have also been shown to
reduce the pain associated with OA both in animal models and in clinical
trials. Applied locally hyaluronans target the disease in the affected limb,
further more the frequency of side effects of hyaluronans is considered
to be low and are generally not serious in nature. There are a number of
puriﬁed hyaluronans available and in recent years hyaluronan hydrogels,
where the material has been crosslinked into networks, have become
available. One of these crosslinked hyaluronan hydrogels is DurolaneTM.
This study has sought to evaluate the effect of Durolane in an in vivo
model of joint pain.
Methods: The model utilized the pain inducing substances bradykinin &
PGE2 administered intra-articular (IA) and unilaterally into the knee joints
of adult female Lewis rats. Rats were randomly allocated to one of
three groups, Durolane, saline or morphine. The saline and Durolane
(20mg/ml) groups were injected IA (50 ul) once (Day 1), 2−4 hours before
the ﬁrst injection of bradykinin (182.25mg) and PGE2 (0.5mg) into the rat
knee. The administration of the pain inducing agents was approximately
45 minutes before initiation of behavioural testing on each testing day. The
morphine acted as a positive control and was administered at 2.5mg/kg
subcutaneously 30 minutes after bradykinin/PGE2 on each testing day.
Behavioural testing was performed at 2 hours and 1, 2, 4, 7, 14, 21 and
28 days and included the assessment of mechanical thresholds at the
knee, weight bearing and locomotor coordination on a rotarod.
Results: Mechanical thresholds at the knee were signiﬁcantly decreased
in saline treated animals. However, a single IA injection of Durolane on
day 1 revealed similar anti-nociceptive effects as did the subcutaneous
injection of morphine on each testing day until the end of the observation
period at day 28. Signiﬁcant differences between saline and Durolane
were seen at days 1, 2, 4, 14 and 28. The incapacitance test showed
that animals treated with Durolane favoured a more 1:1 weight bearing
between treated and untreated limbs. This result was again similar to
those receiving a daily injection of morphine, whereas those treated
with saline favoured the untreated limb, i.e. protecting the injected limb.
Signiﬁcant differences were seen at days 1, 2 and 14 between the
saline and Durolane groups. Rotarod parameters indicating locomotive
function were not signiﬁcantly altered from baseline measures with any of
the treatments administered. This demonstrates that animals could walk
normally and that the pain inducing agents were not causing intolerable
pain in the joints.
Conclusions: This study has demonstrated that a single IA injection of
Durolane provides anti-nociceptive effects until at least day 28, in this
model of induced joint pain.
518 EVALUATION OF ORAL AVACADO/SOYBEAN
UNSAPONIFIABLES USING AN EXPERIMENTAL MODEL OF
EQUINE OSTEOARTHRITIS
D.D. Frisbie, C.E. Kawcak, C.W. McIlwraith. Colorado State University,
Fort Collins, CO, USA
Purpose: Joint disease and speciﬁcally osteoarthritis (OA) is one of the
most prevalent and debilitating diseases affecting horses and humans.
